SEC Comment Letter for OptimizeRx Corp (OPRX) (CIK 0001448431) (OPRX) — May 29, 2018
OptimizeRx Corp (OPRX) (CIK 0001448431)
Date: May 29, 2018 · CIK: 0001448431 · Accession: 0000000000-18-016465
AI Filing Summary & Sentiment
File numbers found in text: 333-225095
Letter
May 29, 2018 William Febbo Chief Executive Officer OptimizeRx Corp. 400 Water Street, Suite 200 Rochester, MI 48307 Re:OptimizeRx Corp. Registration Statement on Form S-1 Filed May 22, 2018 File No. 333-225095 Dear Mr. Febbo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Edwin Kim, Staff Attorney, at (202) 551-3297 or Jan Woo, Legal Branch Chief, at (202) 551-3453 with any questions. Division of Corporation Finance Office of Information Technologies and Services
Show Raw Text
May 29, 2018
William Febbo
Chief Executive Officer
OptimizeRx Corp.
400 Water Street, Suite 200
Rochester, MI 48307
Re:OptimizeRx Corp.
Registration Statement on Form S-1
Filed May 22, 2018
File No. 333-225095
Dear Mr. Febbo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Edwin Kim, Staff Attorney, at (202) 551-3297 or Jan Woo, Legal Branch
Chief, at (202) 551-3453 with any questions.
Division of Corporation Finance
Office of Information Technologies
and Services